Honestly the company has recently provided more information than most other companies of the same size under the same conditions.
Most companies would only say they have reached the events required for completing the trials, and give an approximate time for topline data announcement, which usually ranges from 2 months to several months.
They then usually raise substantially a large sum of cash, much larger than we have experienced with nwbo, and go dark/quiet until the announcement. And usually bad news comes much earlier than expected, and vice versa.
That's all.
Yes you are right on one thing that nwbo management has repeatedly moved the goal posts, which is disappointing to say the least but I think anything has a reason.
If you has done your dd, and committed to investing in this company, you ought to lay your trust on the management, unless you think their interests are not in line with yours.
We all want to see a successful trial results, and as of today the target time for that is still in September.
Why not exercising a bit more of patience, and prepared yourself for possible bear raid or not or a smooth sailing whatever it will come.
Most people are not heavily invested, they want the share price as low as possible so they can cover (for shorts), start new positions, add substantially more shares, etc.
But the nwbo tree is hard to be shake, because of the fact of the known blinded data, unless the placebo or the standard of care arms outlive the historical standard of care patients in a large margin, or the treatment arms. For other cancer indications, it's likely or even very likely but for GBM it seems unlikely based on what we have known.
Market Data 
Markets 
AI
